Crohn’s disease treatment costs with certolizumab pegol (CZP) have been shown to be lower than infliximab (IFX), mainly due to lower CZP drug costs. Here, we examined the one-year (yr) all-cause healthcare resource utilization (HRU) and costs, incurred by CD patients (pts) with CZP vs IFX.